40 studies found for:    Open Studies | "Wilms Tumor"
Show Display Options
Rank Status Study
21 Recruiting Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134
Condition: Malignant Pleural Mesothelioma
Interventions: Biological: WT-1-vaccine Montanide + GM-CSF;   Biological: Montanide adjuvant + GM-CSF
22 Recruiting WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Biological: WT1 Analog Peptide Vaccine;   Biological: Sargramostim (GM-CSF);   Drug: lenalidomide
23 Recruiting Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Condition: Neoplasms, Breast
Interventions: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A;   Biological: Placebo
24 Recruiting Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy
Condition: Malignant Pleural Mesothelioma
Interventions: Biological: WT-1-vaccine Montanide + GM-CSF;   Biological: Montanide adjuvant + GM-CSF
25 Recruiting Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia
Intervention: Biological: WT1 peptide vaccine
26 Recruiting Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: busulfan;   Drug: melphalan;   Drug: fludarabine;   Biological: anti-thymocyte globulin (ATG);   Procedure: a T cell depleted stem cell transplant
27 Recruiting CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Biological: CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs);   Other: Standard of care
28 Unknown  WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Intervention: Biological: WT1 126-134 peptide
29 Recruiting Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Conditions: Leukemia;   Myelodysplastic Syndrome
Intervention: Biological: WT1-sensitized T cells
30 Recruiting Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission
Condition: Acute Myeloid Leukemia
Intervention: Biological: DC vaccine
31 Recruiting Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions: Biological: basiliximab;   Biological: WT1 126-134 peptide vaccine;   Drug: Montanide ISA 51 VG;   Drug: poly ICLC;   Other: laboratory biomarker analysis
32 Recruiting Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Phase Chronic Myelogenous Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Biological: WT1-sensitized T cells;   Biological: aldesleukin;   Other: laboratory biomarker analysis
33 Recruiting Collecting and Storing Tissue From Young Patients With Cancer
Condition: Cancer
Interventions: Genetic: DNA analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis
34 Recruiting Clinical Study of WT2725 in Patients With Advanced Solid Malignancies
Condition: Cancer
Intervention: Biological: WT2725
35 Unknown  External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
Condition: Cancer
Interventions: Drug: indinavir sulfate;   Drug: ritonavir;   Radiation: radiation therapy
36 Unknown  Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
Conditions: Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Neuroblastoma;   Oral Complications;   Ovarian Cancer;   Pain;   Sarcoma
Interventions: Procedure: management of therapy complications;   Procedure: pain therapy
37 Recruiting Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Condition: Cancer
Interventions: Biological: anti-thymocyte globulin;   Biological: rituximab;   Drug: clofarabine;   Procedure: stem cell transplantation
38 Unknown  Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Condition: Cancer
Interventions: Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: medical chart review;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: evaluation of cancer risk factors
39 Unknown  Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
Conditions: Ewing's Sarcoma;   Soft Tissue Sarcoma;   Hepatoblastoma;   Hodgkin's Disease;   Germ Cell Tumor
Intervention: Drug: High-Dose Chemotherapy with Tandem PBSC Rescue.
40 Recruiting Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy
Conditions: Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome
Intervention: Biological: recwt1-A10+AS01B

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page
Indicates status has not been verified in more than two years